Susquehanna International Group’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-224,981
| Closed | -$900K | – | 13126 |
|
|
2025
Q2 | $900K | Buy |
224,981
+118,107
| +111% | +$292K | ﹤0.01% | 7704 |
|
|
2025
Q1 | $97.3K | Buy |
106,874
+45,824
| +75% | +$63.5K | ﹤0.01% | 11559 |
|
|
2024
Q4 | $169K | Buy |
+61,050
| New | +$232K | ﹤0.01% | 10912 |
|
|
2024
Q3 | – | Sell |
-14,114
| Closed | -$62.9K | – | 12477 |
|
|
2024
Q2 | $62.9K | Sell |
14,114
-16,040
| -53% | -$77.8K | ﹤0.01% | 11314 |
|
|
2024
Q1 | $231K | Sell |
30,154
-13,503
| -31% | -$74.1K | ﹤0.01% | 10288 |
|
|
2023
Q4 | $186K | Buy |
+43,657
| New | +$155K | ﹤0.01% | 10753 |
|
|
2023
Q3 | – | Sell |
-16,404
| Closed | -$83.4K | – | 12453 |
|
|
2023
Q2 | $91.4K | Buy |
+16,404
| New | +$97K | ﹤0.01% | 11012 |
|
|
2021
Q2 | – | Sell |
-17,091
| Closed | -$338K | – | 12898 |
|
|
2021
Q1 | $338K | Buy |
+17,091
| New | +$377K | ﹤0.01% | 10354 |
|
|
2020
Q4 | – | Sell |
-8,469
| Closed | -$223K | – | 11355 |
|
|
2020
Q3 | $223K | Buy |
+8,469
| New | +$210K | ﹤0.01% | 9284 |
|
Susquehanna International Group's INZY Position: Q3 2025 in Review
Susquehanna International Group sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 224,981 shares — an estimated $900K sold.
Susquehanna International Group first reported a position in INZY in Q3 2020 and held it in 9 quarters. The position peaked at $900K in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Susquehanna International Group reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Susquehanna International Group sold 224,981 Inozyme Pharma shares in Q3 2025, an estimated $900K.
- Susquehanna International Group first reported a position in Inozyme Pharma in Q3 2020 and held it in 9 quarters.
- Susquehanna International Group's Inozyme Pharma position peaked at $900K in Q2 2025.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.